Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD
A Long-term Follow-up Study to Evaluate the Safety and Effectivity of AL-001 Ophthalmic Injection in Subjects with Wet Age-related Mecular Degeneration (wAMD)
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: AnlongBio
- Phone Number: +86-010-80414166
- Email: info@anlongbio.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China
- Recruiting
- Chinese Academy of Medical Sciences & Peking Union Hospital
-
Contact:
- YouxinChen
- Phone Number: +86-010-65296358
- Email: chenyouxinpumch@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- The subjects enrolled in AL-001 study and received AL-001 ophthalmic injection.
- The subject or their legal representative agrees to participate in this study and signs a written ICF.
- The subjects are willing and able to follow planned visits and procedures.
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
The subjects received AL-001 ophthalmic injection
Evaluate long-term safety and efficacy
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
AE/SAE
Time Frame: month 48
|
Incidence and severity of ophthalmic and systematic AE/SAE.
|
month 48
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Best Corrected Visual Acuity(BCVA)
Time Frame: month 48
|
Change in BCVA from baseline
|
month 48
|
|
The mean and frequency of anti-VEGF injections
Time Frame: month 48
|
The mean and frequency of subjects with wAMD receiving anti-VEGF injections
|
month 48
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- AL-001-LT
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.